For cancer patients, hair loss is often one of the most distressing side effects of treatment, striking at a core part of personal identity. In response, many turn to biotin (vitamin B7), a supplement widely marketed online as a harmless way to strengthen hair and nails. However, medical experts are raising a critical warning: biotin supplements can interfere with essential blood tests, potentially leading to misdiagnosed conditions or delayed cancer treatment.
Brittany Dulmage, MD, an oncodermatologist at The Ohio State University Comprehensive Cancer Center, highlights that while biotin is popular, there is little evidence it aids hair regrowth during or after chemotherapy. More importantly, its presence in the bloodstream can distort lab results for markers used to monitor prostate, thyroid, ovarian, and breast cancers.
The Hidden Risk: Skewed Diagnostic Data
Biotin is a water-soluble vitamin found abundantly in common foods like eggs, meat, dairy, and vegetables. True biotin deficiency is rare, meaning extra supplementation rarely provides additional health benefits for the general population. Yet, its chemical structure poses a significant problem for modern diagnostic testing.
Many laboratory assays use biotin-streptavidin technology to detect hormones and proteins. When a patient has high levels of biotin in their blood from supplements, it can disrupt these chemical reactions, causing false readings.
“Biotin does not actually change the levels of hormones in the body, but it interferes with the way those levels could be checked when blood work is done,” explains Dr. Dulmage.
The consequences of these skewed results can be severe:
- False Lows: Tests for prostate-specific antigen (PSA) or thyroid-stimulating hormone (TSH) may appear lower than they actually are. This can mask cancer recurrence in survivors, giving a false sense of security.
- False Highs: Levels of reproductive hormones like estrogen and testosterone may appear artificially elevated, potentially leading to unnecessary delays in therapy or incorrect treatment adjustments.
- Emergency Risks: Biotin can also affect troponin levels, a critical marker for heart attacks. In an emergency situation, a patient cannot wait to stop taking supplements, risking a misdiagnosis of cardiac events.
Patient Experience: The Cost of Misinformation
Anna Malagoli, a breast cancer survivor from Columbus, Ohio, experienced this diagnostic interference firsthand. Like many patients, she sought to regain her long, curly hair after treatment. Relying on internet advice, she began taking high doses of biotin without realizing the potential impact on her medical monitoring.
“My lab results were inconsistent. They just didn’t balance out with what I was feeling so that was a red flag,” Malagoli recalls. It was only after consulting with Dr. Dulmage that she connected her supplement use to the erratic test results.
Malagoli’s story is not unique. Dr. Dulmage notes that more than half of the patients visiting her oncology dermatology clinic for hair loss issues are taking supplements they started independently, often based on online trends or word-of-mouth recommendations rather than clinical evidence.
Safer, Proven Alternatives Exist
To combat this issue, Dr. Dulmage and colleagues published a study in JCO Oncology Practice urging oncologists to discuss hair loss management openly with patients. The goal is to shift focus from unproven supplements to clinically validated treatments.
Minoxidil, an FDA-approved topical treatment (available as lotions or foams), is recommended as a safer and more effective alternative for managing chemotherapy-induced hair loss. While biotin offers no guaranteed benefit for hair regrowth in non-deficient individuals, minoxidil has a established track record of efficacy.
- For those currently taking biotin: Dr. Dulmage advises stopping the supplement at least 72 hours before any scheduled blood work. However, she emphasizes that this is not a fail-safe strategy, especially for unexpected tests like troponin checks.
- The best approach: Given the rarity of biotin deficiency and the risks of diagnostic interference, Dr. Dulmage recommends avoiding biotin supplements altogether for hair loss purposes.
“If you have been trying minoxidil for several months and not seeing any improvement, or want to know about other options, see a dermatologist,” Dr. Dulmage advises. “There are many other types of treatments that may be an option.”
Conclusion
While the desire to restore normalcy during and after cancer treatment is understandable, self-medicating with biotin poses a tangible risk to patient safety. By skewing critical lab results, these supplements can obscure the true picture of a patient’s health, potentially delaying vital care. Patients are urged to consult their oncology team before starting any new supplement and to consider FDA-approved alternatives like minoxidil for hair loss management.
